A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy.
Phase of Trial: Phase I
Latest Information Update: 07 May 2013
At a glance
- Drugs MVA BN HER2 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 07 May 2013 Additional lead centre (Bavarian Nordic) added as reported by ClinicalTrials.gov.
- 24 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.